AHEAD 3-45 Study: Phase III, placebo-controlled trial of Lecanemab in participants with preclinical Alzheimer’s disease
M
Martin Farlow, MD
Primary Investigator
Recruiting
55-80 years
All
Phase
3
12 participants needed
2 Locations
Overview
The purpose of this study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer’s disease (AD) Cognitive Composite 5 (PACC5) at 216 weeks of treatment
Who is Eligible
- Ages 55-80
- No diagnosis of mild cognitive impairment or Alzheimer’s disease
- No medications for memory, must be able to complete MRI
- No history of stroke, seizures, or cancer in the last 5 years
What is Involved
- In-person appointments at the IUH Neuroscience Center, optional home health infusions after first 6 months
- IV infusions every 2 or 4 weeks for 22 months, then every 4 weeks for 24 months. Infusions can be administered at home at first 6 months.
Compensation
- Compensation available via payment card for each completed appointment
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's Disease
-
Age: Between 55 Years - 80 Years
-
Gender: All
Updated on
15 May 2024.
Study ID: 2003720044
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
